Kosin Med J.  2012 Dec;27(2):91-97. 10.7180/kmj.2012.27.2.91.

Predictive Value of Maternal Serum Markers for Preeclampsia

• Oh SH
• Kim HY

• KMID: 2308516
• DOI: http://doi.org/10.7180/kmj.2012.27.2.91

Abstract

The study performed a systematic review of screening for preeclampsia with the combination of vascular parameters and maternal serum markers in the first and early second trimester. We identified eligible studies through a search of Medline, and, for each included study, we focused on the relationship between the maternal serum markers and preeclampsia. In the selected literature, a combination of maternal serum markers was analyzed, also. Several tests suggested moderate or convincing prediction of early preeclampsia, but screening for late preeclampsia was poor. Literatures for serum markers were selected. Each serum marker was identified independently, and where relevant, a combination of these markers was analyzed. Encouraging results for the first trimester screening were observed when it was combined with other markers. Even in the first trimester of pregnancy, we can present the reliable results for the prediction of early preeclampsia. Detection rate for combination markers may yield higher detection rate and be promising to identify patients at high risk of developing preeclampsia.

Keyword

Blood Pressure; Biological Markers; Pre-Eclampsia; Screening

MeSH Terms

Biomarkers
Blood Pressure
Female
Humans
Mass Screening
Pre-Eclampsia
Pregnancy
Pregnancy Trimester, First
Pregnancy Trimester, Second

Reference

1.Saftlas AF., Olson DR., Franks AL., Atrash HK., Pokras R. Epidemiology ofpreeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol. 1990. 163:460–5.

2.Borzychowski AM., Sargent IL., Redman CW. Inflammationand pre-eclampsia. Semin Fetal Neonatal Med. 2006. 11:309–16.

3.Steegers EA., von Dadelszen P., Duvekot JJ., Pijnenborg R. Pre-eclampsia. Lancet. 2010. 376:631–44.

4.Huppertz B. Placental origins of preeclampsia: challengingthe current hypothesis. Hypertension. 2008. 51:970–5.

5.Leslie K., Thilaganathan B., Papageorghiou A. Early prediction andprevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011. 25:343–54.

6.Yu CK., Smith GC., Papageorghiou AT., Cacho AM., Nicolaides KH. Fetal Medicine Foundation Second Trimester Screening Group. An integrated model for the prediction ofpreeclampsia using maternal factors and uterine artery Doppler velocimetry inunselected low-risk women. Am J Obstet Gynecol. 2005. 193:429–36.

7.Khalil A., Cowans NJ., Spencer K., Goichman S., Meiri H., Harrington K. First-trimester markers for the prediction ofpreeclampsia in women with a-priori high risk. Ultrasound Obstet Gynecol. 2010. 35:671–9.

8.Giguère Y., Charland M., Bujold E., Bernard N., Grenier S., Rousseau F, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Ann BiolClin. 2011. 69:257–1.

9.Farina A., Zucchini C., Sekizawa A., Purwosunu Y., de Sanctis P., Santarsiero G, et al. Performance of messenger RNA scirculating in maternal blood in the prediction of preeclampsia at 10-14 weeks. Am J Obstet Gynecol. 2010. 203:e1–7.

10.Conde-Agudelo A., Villar J., Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol. 2004. 104:1367–91.

11.Redman CW. Current topic: pre-eclampsia and the placenta. Placenta. 1991. 12:301–8.

12.Costa SL., Proctor L., Dodd JM., Toal M., Okun N., Johnson JA, et al. Screening for placental insufficiency in high-risk pregnancies: is earlier better? Placenta. 2008. 29:1034–40.

13.Cindrova-Davies T., Spasic-Boskovic O., Jauniaux E., Charnock-Jones DS., Burton GJ. Nuclear factor-kappa B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in response to oxidative stress: effects of antioxidant vitamins. Am J Pathol. 2007. 170:1511–20.

14.Bosio PM., Cannon S., McKenna PJ., O'Herlihy C., Conroy R., Brady H. Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia. BJOG. 2001. 108:709–15.

15.Bersinger NA., Smárason AK., Muttukrishna S., Groome NP., Redman CW. Women with preeclampsia have increased serum levels ofpregnancy-associated plasma protein A (PAPP-A), inhibinA, activin A and soluble E-selectin. Hypertens Pregnancy. 2003. 22:45–55.

16.Giudice LC., Conover CA., Bale L., Faessen GH., Ilg K., Sun I, et al. Identification andregulation of the IGFBP-4 protease and its physiologicalinhibitor in human trophoblasts and endometrial stroma: evidencefor paracrine regulation of IGF-II bioavailability in theplacental bed during human implantation. J Clin Endocrinol Metab. 2002. 87:2359–66.

17.Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. 2010. 8:102.

18.Lee LC., Sheu BC., Shau WY., Liu DM., Lai TJ., Lee YH, et al. Mid-trimester beta-hCG levels incorporated in a multifactorial model for the prediction of severe pre-eclampsia. Prenat Diagn. 2000. 20:738–43.

19.Birdsall M., Ledger W., Groome N., Abdalla H., Muttukrishna S. Inhibin A and activin A in the first trimester of human pregnancy. J Clin Endocrinol Metab. 1997. 82:1557–60.

20.Muttukrishna S., Knight PG., Groome NP., Redman CW., Ledger WL. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet. 1997. 349:1285–8.

21.Sekizawa A., Purwosunu Y., Yoshimura S., Nakamura M., Shimizu H., Okai T, et al. PP13 mRNA expression in trophoblasts from preeclamptic placentas. Reprod Sci. 2009. 16:408–13.

22.Burger O., Pick E., Zwickel J., Klayman M., Meiri H., Slotky R, et al. Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta. 2004. 25:608–22.

23.Lockwood CJ., Krikun G., Caze R., Rahman M., Buchwalder LF., Schatz F. Decidual cell expressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis. Ann N Y AcadSci. 2008. 1127:67–72.

24.Levine RJ., Maynard SE., Qian C., Lim KH., England LJ., Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004. 350:672–83.

25.Erez O., Romero R., Espinoza J., Fu W., Todem D., Kusanovic JP, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008. 21:279–87.

26.Gack S., Marmé A., Marmé F., Wrobel G., Vonderstrass B., Bastert G, et al. Preeclampsia: increased expression of soluble ADAM 12. J Mol Med. 2005. 83:887–96.

27.Spencer K., Cowans NJ., Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn. 2008. 28:212–6.

28.Wortelboer EJ., Koster MP., Cuckle HS., Stoutenbeek PH., Schielen PC., Visser GH. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset preeclampsia. BJOG. 2010. 117:1384–9.